BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

759 related articles for article (PubMed ID: 24192217)

  • 1. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.
    Wattjes MP; Richert ND; Killestein J; de Vos M; Sanchez E; Snaebjornsson P; Cadavid D; Barkhof F
    Mult Scler; 2013 Dec; 19(14):1826-40. PubMed ID: 24192217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.
    Yousry TA; Pelletier D; Cadavid D; Gass A; Richert ND; Radue EW; Filippi M
    Ann Neurol; 2012 Nov; 72(5):779-87. PubMed ID: 23280794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab.
    Kleinschmidt-DeMasters BK; Miravalle A; Schowinsky J; Corboy J; Vollmer T
    J Neuropathol Exp Neurol; 2012 Jul; 71(7):604-17. PubMed ID: 22710964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI.
    Wattjes MP; Barkhof F
    Curr Opin Neurol; 2014 Jun; 27(3):260-70. PubMed ID: 24739400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy.
    Metz I; Radue EW; Oterino A; Kümpfel T; Wiendl H; Schippling S; Kuhle J; Sahraian MA; Gray F; Jakl V; Häusler D; Brück W
    Acta Neuropathol; 2012 Feb; 123(2):235-45. PubMed ID: 22057786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of progressive multifocal leukoencephalopathy and natalizumab.
    Aksamit AJ
    Neurologist; 2006 Nov; 12(6):293-8. PubMed ID: 17122725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy.
    Eisele P; Szabo K; Hornberger E; Griebe M; Hennerici MG; Kieseier BC; Gass A
    J Neuroimaging; 2014; 24(4):425-8. PubMed ID: 23323645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical MRI features at early onset natalizumab-associated progressive multifocal leukoencephalopathy: a case report.
    Piola M; Di Palma F; Mascoli N; Binda S; Arnaboldi M; Rezzonico M
    J Neurol Sci; 2014 May; 340(1-2):213-4. PubMed ID: 24642511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS.
    Wattjes MP; Wijburg MT; Vennegoor A; Witte BI; de Vos M; Richert ND; Uitdehaag BM; Barkhof F; Killestein J;
    J Neurol Neurosurg Psychiatry; 2016 Aug; 87(8):879-84. PubMed ID: 26369555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS.
    Wattjes MP; Wijburg MT; van Eijk J; Frequin S; Uitdehaag BMJ; Barkhof F; Warnke C; Killestein J;
    J Neurol Neurosurg Psychiatry; 2018 May; 89(5):535-541. PubMed ID: 29142146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab.
    Blinkenberg M; Sellebjerg F; Leffers AM; Madsen CG; Sørensen PS
    Mult Scler; 2013 Aug; 19(9):1226-9. PubMed ID: 23508652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MRI pattern in asymptomatic natalizumab-associated PML.
    Wattjes MP; Vennegoor A; Steenwijk MD; de Vos M; Killestein J; van Oosten BW; Mostert J; Siepman DA; Moll W; van Golde AE; Frequin ST; Richert ND; Barkhof F
    J Neurol Neurosurg Psychiatry; 2015 Jul; 86(7):793-8. PubMed ID: 25205744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
    N'gbo N'gbo Ikazabo R; Mostosi C; Quivron B; Delberghe X; El Hafsi K; Lysandropoulos AP
    Clin Ther; 2016 Mar; 38(3):670-5. PubMed ID: 26856928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.
    Wattjes MP; Wijburg MT; Vennegoor A; Witte BI; Roosendaal SD; Sanchez E; Liu Y; Martins Jarnalo CO; Richert ND; Uitdehaag BM; Barkhof F; Killestein J
    Mult Scler; 2016 Aug; 22(9):1174-83. PubMed ID: 26564995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?
    Wattjes MP; Vennegoor A; Mostert J; van Oosten BW; Barkhof F; Killestein J
    J Neurol; 2014 Jun; 261(6):1139-43. PubMed ID: 24705790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications.
    Igra MS; Paling D; Wattjes MP; Connolly DJA; Hoggard N
    Br J Radiol; 2017 Jun; 90(1074):20160721. PubMed ID: 28362522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis.
    Sahraian MA; Radue EW; Eshaghi A; Besliu S; Minagar A
    Eur J Neurol; 2012 Aug; 19(8):1060-9. PubMed ID: 22136455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case of subtentorial progressive multifocal leucoencephalopathy in a patient treated with natalizumab].
    Simaniv TO; Ivanova MV; Bryukhov VV; Zakharova MN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(2. Vyp. 2):98-106. PubMed ID: 31156248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic resonance imaging changes following natalizumab discontinuation in multiple sclerosis patients with progressive multifocal leukoencephalopathy.
    Hodel J; Bapst B; Outteryck O; Verclytte S; Deramecourt V; Benadjaoud MA; Pruvo JP; Vermersch P; Leclerc X
    Mult Scler; 2018 Dec; 24(14):1902-1908. PubMed ID: 29343163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.
    Gheuens S; Smith DR; Wang X; Alsop DC; Lenkinski RE; Koralnik IJ
    Neurology; 2012 May; 78(18):1390-3. PubMed ID: 22517104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.